{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:29:32Z","timestamp":1761863372493},"reference-count":30,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T00:00:00Z","timestamp":1419206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eradication of hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infection, at least in compensated patients, can help improve the outcomes of liver disease such as cirrhosis, hepatocellular carcinoma (<jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>) and liver transplantation, as well as perhaps extra\u2010hepatic complications such as diabetes and cardiovascular risk. In the past few years, the landscape of antiviral therapy has evolved at a breathtaking pace from pegylated interferon (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) plus ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) to <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010based strategies combining direct acting antivirals (<jats:styled-content style=\"fixed-case\">DDA<\/jats:styled-content>s) with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> and finally <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010free combinations of <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s. In particular with these most recent developments, treatment regimens have become shorter, safer and even more effective, with a wide range of indications. Nevertheless, research continues and newer antiviral drugs are still under development. At a point when a &gt;90% sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) is being claimed with all new available regimens, pharmacological and clinical research should be addressing unresolved areas, such as cases of suboptimal <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> or to increase effectiveness rather than pursuing the development of new \u2018me\u2010too\u2019 drugs. The issues which should be given priority for further development include the following:\n<jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Improving the results of IFN\u2010free regimens in patients with genotype 3 (HCV\u20103) infection.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Identifying the indications for the treatment in patients with compensated and decompensated cirrhosis.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Identifying standardized or personalized backup strategies in patients who do not respond to IFN\u2010free regimens.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><jats:p>Finally, because of financial constraints, the high cost of <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010free strategies prevents their universal use in <jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content> patients and coverage by national healthcare systems. Thus, efforts must be made to document cost\u2010effectiveness in all clinical scenarios and to develop more affordable <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010free regimens.<\/jats:p>","DOI":"10.1111\/liv.12714","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T10:26:34Z","timestamp":1419243994000},"page":"4-10","source":"Crossref","is-referenced-by-count":24,"title":["Current and future <scp>HCV<\/scp> therapy: do we still need other anti\u2010<scp>HCV<\/scp> drugs?"],"prefix":"10.1111","volume":"35","author":[{"given":"Salvatore","family":"Petta","sequence":"first","affiliation":[{"name":"Sezione di Gastroenterologia e Epatologia Di.Bi.M.I.S. University of Palermo Palermo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[{"name":"Sezione di Gastroenterologia e Epatologia Di.Bi.M.I.S. University of Palermo Palermo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,22]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Hepatitis B and C in the EU neighbourhood: prevalence burden of disease and screening policies. European Centre for Disease Prevention and Control September 2010."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306102"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20073"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23528"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.11.018"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00005-8"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.058"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"issue":"1","key":"e_1_2_6_13_1","first-page":"733A","article-title":"Sofosbuvir \u00fe ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial","volume":"58","author":"Zeuzem S","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12423"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_6_23_1","unstructured":"LawitzE PoordadF BrainardD.Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV\u2010infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR\u20102 study. Abstract LB\u20104. 64th Annual Meeting of the American Association for the Study of Liver Diseases. Washington DC 1\u20135 November 2013."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)61036\u20109"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.018"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60008-8"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60057-X"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.009"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.011"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12714","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:59:35Z","timestamp":1694555975000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,22]]},"references-count":30,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/liv.12714"],"URL":"https:\/\/doi.org\/10.1111\/liv.12714","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,22]]}}}